Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.56 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.56 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.56 |
| ▸ | DRD4 | P21917 | 10/20 | 0.45 |
| ▸ | DRD2 | P14416 | 8/20 | 0.45 |
| ▸ | HTR2A | P28223 | 8/20 | 0.45 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.44 |
| ▸ | HTR1D | P28221 | 1/20 | 0.43 |
| ▸ | HTR1B | P28222 | 1/20 | 0.43 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.41 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.41 |
| ▸ | DPP4 | P27487 | 1/20 | 0.41 |
| ▸ | PREP | P48147 | 1/20 | 0.41 |
| ▸ | MBTPS1 | Q14703 | 1/20 | 0.40 |
| ▸ | VEGFA | P15692 | 1/20 | 0.39 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4579303 | 0.80 | HDAC1 (0.55) | HDAC8HDAC6HDAC1HTR1DHTR1B | |
| SCHEMBL4579157 | 0.79 | HDAC1 (0.60) | HDAC8HDAC6HDAC1 | |
| SCHEMBL4579152 | 0.79 | HDAC1 (0.60) | HDAC8HDAC6HDAC1 | |
| SCHEMBL4580911 | 0.78 | DRD4 (0.60) | DRD4DRD2HTR2ACHRM4 | |
| SCHEMBL4579575 | 0.78 | DRD4 (0.59) | HDAC1DRD4DRD2HTR2ACHRM4 | |
| SCHEMBL4579392 | 0.77 | HPGDS (0.46) | HDAC1DRD4DRD2HTR2ACHRM4 | |
| SCHEMBL14155889 | 0.76 | HDAC1 (0.52) | HDAC8HDAC6HDAC1HTR1DHTR1B | |
| SCHEMBL4669170 | 0.76 | HDAC1 (0.48) | HDAC1DRD4DRD2HTR2ACHRM4 | |
| SCHEMBL4578591 | 0.74 | DRD4 (0.42) | HDAC1DRD4DRD2HTR2ACHRM4 | |
| SCHEMBL1067900 | 0.74 | CHRM4 (0.55) | HDAC8HDAC6HDAC1DRD4DRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2007720-B1 | BENZAMIDE DERIVATIVES AS INHIBITORS OF HISTONE DEACETYLASE | METHYLGENE INC (CA) | 2013-12-25 | — | — | EP | disclosed |
| US-8598168-B2 | Inhibitors of histone deacetylase | METHYLGENE INC. (CA) | 2013-12-03 | — | — | US | disclosed |
| US-20080132503-A1 | Inhibitors of Histone Deacetylase | METHYLGENE INC. (CA) | 2008-06-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080132503-A1 | Inhibitors of Histone Deacetylase | HDAC1, HDAC5, HDAC3 | HDAC8 9/4885HDAC6 6/4885HDAC1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.